CXCL5/ENA-78 Antibody (33160) [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

CXCL5, also known as epithelial cell-derived-neutrophil-activating-peptide (ENA78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR^- CXC chemokines which are angiostatic. Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR⁺ chemokines, it shares 77% aa sequence identity with CXCL6/GCP2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP2, and CXCL8/IL8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis. Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers. Full length CXCL5 (78 aa) is trimmed at the N-terminal end by Cathepsin G and chymotrypsin to ENA74 (74 aa) and ENA70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5. CXCL5 exerts its effects primarily through interactions with CXCR2. It also binds DARC, a decoy chemokine receptor which can limit CXCR2-mediated responses.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 4 applications: ELISA Development, IHC, Neutralization, Western Blot.

Showing Publications 1 - 7 of 7.

Publications using MAB254	Applications	Species
Chen, C;Lin, LY;Chen, JW;Chang, TT; CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus Cardiovascular diabetology 2023-07-07 [PMID: 37420254] (Western Blot, Neutralization, Human)	Western Blot, Neutralization	Human
C Sorrentino, L D'Antonio, SL Ciummo, C Fieni, L Landuzzi, F Ruzzi, S Vespa, P Lanuti, LV Lotti, PL Lollini, E Di Carlo CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality Journal of hematology & oncology, 2022-10-13;15(1):145. 2022-10-13 [PMID: 36224639] (Neutralization, Human)	Neutralization	Human
B Wu, J Wang, X Wang, M Zhu, F Chen, Y Shen, Z Zhong CXCL5 expression in tumor tissues is associated with poor prognosis in patients with pancreatic cancer Oncology Letters, 2020-09-18;20(5):257. 2020-09-18 [PMID: 32994820] (IHC, Human)	IHC	Human
Y Zhao, X Zhang, H Zhao, J Wang, Q Zhang CXCL5 secreted from adipose tissue-derived stem cells promotes cancer cell proliferation Oncol Lett, 2017-12-05;15(2):1403-1410. 2017-12-05 [PMID: 29434831] (Neutralization, Human)	Neutralization	Human
Kuravi S, McGettrick H, Satchell S, Saleem M, Harper L, Williams J, Rainger G, Savage C Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk. J Immunol, 2014-05-28;193(1):234-43. 2014-05-28 [PMID: 24872191] (Neutralization, Human)	Neutralization	Human
Sundaram K, Rao D, Ries W, Reddy S CXCL5 stimulation of RANK ligand expression in Paget's disease of bone. Lab Invest, 2013-02-25;93(4):472-9. 2013-02-25 [PMID: 23439434] (ELISA Development, Human)	ELISA Development	Human
Zhang H, Ning H, Banie L, Wang G, Lin G, Lue TF, Lin CS Adipose tissue-derived stem cells secrete CXCL5 cytokine with chemoattractant and angiogenic properties. Biochem. Biophys. Res. Commun., 2010-10-27;402(3):560-4. 2010-10-27 [PMID: 21034724] (Neutralization, Human)	Neutralization	Human

Array MAB254

• CXCL5/ENA-78 Antibodies
• CXCL5/ENA-78 Antibody Pair
• CXCL5/ENA-78 ELISA Kits
• CXCL5/ENA-78 Lysate
• CXCL5/ENA-78 Proteins
• CXCL5/ENA-78 ELISAs
• CXCL5/ENA-78 Proteins and Enzymes